Dong-A Pharm launches Pureka, a stick-pack salad with 41 fruits and vegetables
Dong-A Pharm said Tuesday it has launched Pureka, a single-serve stick pack that contains 41 fruits and vegetables for convenient consumption.
The company said the product targets consumers seeking to improve eating habits for health management. It is positioned around the “reverse eating” trend — eating vegetables, then protein, then carbohydrates — aimed at moderating post-meal blood sugar spikes, offering a way to consume vegetables before a meal.
The brand name combines “Pure” and “Eureka,” the company said, to convey the idea of discovering a simple, “pure” daily health routine. Each stick pack is designed for easy use without washing or prep, and includes a dual blend of soluble and insoluble dietary fiber, plus probiotics and digestive enzymes, the company said.
Pureka comes in two versions: “Pureka Greens Watermix,” a powder mixed with water, and “Pureka Greens Crunch,” an ultra-small tablet meant to be chewed.
Yuhan marks 100th anniversary with campaign to collect company historical materials
Yuhan said Tuesday it will run a campaign to collect historical materials tied to the company as it marks its 100th anniversary.
The campaign aims to help restore the history of founder Dr. Yu Ilhan and Yuhan’s 100 years, the company said, by gathering a wide range of records, including items held by individuals.
Eligible materials include items produced or used before 2000, such as photos and documents related to Dr. Yu and Yuhan, books, and museum-type items including products and souvenirs. The company said it will accept submissions ranging from personal daily records to materials with historical significance.
Submissions will be accepted through Feb. 27 via online or text message, with a brief description and photos attached, the company said.
Yuhan said it will review submissions based on archival value, preservation condition and potential use before selecting items. Selected materials will be used for Yuhan’s 100th anniversary archive, exhibitions and content production, it said.
Celltrion says Omliclo gains traction in Spain, a key European market
Celltrion said Tuesday that Omliclo (omalizumab), a treatment for chronic spontaneous urticaria and allergic asthma, is accelerating its market expansion in Spain.
Celltrion’s Spain unit was selected late last year as the top-ranked supplier in a public tender in Catalonia, a major region, the company said. It was also chosen as the top-ranked bidder in a tender to supply all public medical institutions in the Basque Country and completed a supply contract last month, it said.
Omliclo is now prescribed across about 260 public and private hospitals in Spain, Celltrion said. The company said it plans to use its Spain strategy and results to expand prescriptions across Europe.
Samsung Biologics signs vaccine manufacturing partnership with CEPI
Samsung Biologics said Tuesday it signed a partnership agreement with the Coalition for Epidemic Preparedness Innovations, or CEPI, on Monday at the Conrad Seoul hotel in Yeouido, Seoul, to join a vaccine manufacturing facility network.
Under the partnership, Samsung Biologics will be designated a “preferred” manufacturer for vaccines CEPI is supporting, the company said.
In the event of a pandemic, Samsung Biologics said it will produce up to 50 million doses of vaccine and drug substance that can be converted into up to 1 billion doses of drug product vaccine, at CEPI’s request. Vaccines produced by Samsung Biologics would be supplied to South Korea first upon CEPI’s request, it said.
The company said the partners will also conduct simulation exercises for rapid response, using a scenario involving an outbreak of wild-type H5 influenza. The drills are intended to verify the speed and stability of end-to-end capabilities from antigen development through manufacturing and supply, it said.
Samsung Biologics said the two sides also plan to work together to strengthen chemistry, manufacturing and controls process development for recombinant protein vaccines and to expand standby production capacity.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.